



University of Virginia Health System Installs Second CorPath System[®], Supports UVA “Be Safe” Initiative for Patients and Staff

CorPath’s radiation protection capability a key part of “Be Safe”

Waltham, MA – April 9, 2015 – **Corindus Vascular Robotics [OTCQB: CVRS]**, a leading developer of precision vascular robotics, today announced that the University of Virginia Health System (UVA) has installed a second **CorPath System**, the only FDA-cleared system for robotic-assisted PCI. The second system supports UVA’s continuing efforts behind its “Be Safe” initiative, which is designed to make the health system the safest place in healthcare for patients and employees alike. The initiative focuses on training UVA team members to identify issues that improve safety, workflow and outcomes by increasing protection of operators in the cath lab, where risks from harmful radiation exposure and traditional protection methods continue to be a major concern.

“Using robotic-assisted PCI, we are able to protect interventional cardiologists from the orthopedic strain and risks of radiation exposure while performing interventional procedures,” said Michael Ragosta, MD, Medical Director for Interventional Cardiology, UVA. “Beyond the safety advances afforded by the system, the enhanced precision, visualization and measurement may lead to improved patient care.”

During a CorPath robotic-assisted PCI procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit, and advances guidewires and stents with millimeter-by-millimeter precision. Along with the addition of robotic precision to procedures, [the PRECISE clinical trial¹](#) demonstrated that while using the CorPath System physician radiation exposure during procedures was reduced by 95 percent.

For more information, visit www.corindus.com.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company’s FDA-cleared CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help physicians potentially provide better clinical outcomes and minimize the costs associated with complications through improper stent placement during manual PCI procedures. Corindus stands behind its product with its unique \$1,000 hospital credit “One Stent Program.” For additional information, visit www.corindus.com, and follow @CorindusInc.

¹PRECISE Trial was sponsored by Corindus, Inc.

Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and

uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control. Examples of such statements include statements regarding the potential benefits of our CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. More information on potential factors that could affect Corindus’ financial results is included from time to time in the “Forward Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Corindus’ periodic and current filings with the SEC, as well as those discussed under the “Risk Factors” and “Forward Looking Statements” section of Corindus’ Annual Report on Form 10-K filed with the SEC on March 30, 2015 and available on Corindus’ website at <http://www.corindus.com/about-corindus/investor-relations>. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.

###

Media Contacts:

Corindus Vascular Robotics

Brett Prince

(508) 653-3335 ext. 231

brett.prince@corindus.com

Brittney Quinn

(203) 504-8230

corindus@knbpr.com